Bevacizumab in lung cancer: hurdles in clinical development.

摘要

Targeted treatments focusing on inhibition of angiogenesis and epidermal-growth-factor-receptor-mediated signal transduction offer new treatment options for patients with advanced non-small-cell lung cancer (NSCLC). Clinical benefits have been shown for bevacizumab cetuximab, gefitinib, and erlotinib. Overall, however, the clinical development of targeted therapies for NSCLC has been associated with several difficulties. Toxic effects have been a greater than anticipated problem in the development of many targeted agents.